Author

S. M. Nashir Udden

The University of Texas Southwestern Medical CenterORCID 0000-0003-3196-2803Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Organism:mouse· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Kamal PandeyiD· 2 shared Prasanna G. AlluriiD· 2 shared Baishan JiangiD· 1 shared Chantal Vidal· 1 shared Cheryl M. LewisiD· 1 shared Nicole GuenthneriD· 1 shared Noelle Sevilir WilliamsiD· 1 shared Sunati SahooiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

9 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Kamal PandeyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintFeb 18, 2026

Radiation synergizes with BET inhibition to stimulate durable, systemic anti-tumor immunity in murine cancer models

Nicole Guenthner, Chantal Vidal, Kamal Pandey…·Prasanna G. Alluri

This study shows that combining radiation therapy with BET inhibition enhances anti-tumor immunity in immunologically cold tumors in mice.

DOI 10.64898/2026.02.16.706212

mouseexperimental assay

Cancer BiologybioRxivPreprintNov 11, 2025

The non-kinase function of CDK6 is a key driver of acquired resistance to CDK4/6 inhibitors in Estrogen Receptor-positive breast cancer

S. M. Nashir Udden, Baishan Jiang, Kamal Pandey…·Prasanna G. Alluri

This study shows that CDK6's non-kinase function drives resistance to CDK4/6 inhibitors in ER+ breast cancer, challenging the assumption that kinase inhibition is the main therapeutic target.

DOI 10.1101/2025.11.11.687883

humanbulk RNA-seq